申请人:BOEHRINGER INGELHEIM (CANADA) LTD.
公开号:EP1437362A1
公开(公告)日:2004-07-14
The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus.
wherein W is CH or N; R21 is H, halo, C1-6 alkyl, cycloalkyl, haloalkyl, C1-6 alkoxy, cycloalkoxy, hydroxy, or N(R23)2, wherein each R23 is independently H, C1-6 alkyl or cycloalkoxy; and R22 is H, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 thioalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, C2-7 alkoxyalkyl, C3-6 cycloalkyl, C6 or 10 aryl or Het, wherein Het is a five-, six-, or seven-membered saturated or unsaturated heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur; said cycloalkyl, aryl or Het being substituted with R24, wherein R24 is H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, NO2, N(R25)2, NH-C(O)-R25; or NH-C(O)-NH-R25, wherein each R25 is independently: H, C1-6 alkyl or C3-6 cycloalkyl; or R24 is NH-C(O)-OR26 wherein R26 is C1-6 alkyl or C3-6 cycloalkyl; R3 is hydroxy, NH2, or a group of formula - NH-R31, wherein R31 is C6 or 10 aryl, heteroaryl, -C(O)-R32, -C(O)-OR32 or -C(O)-NHR32, wherein R32 is: C1-6 alkyl or C3-6 cycloalkyl; D is a 5 to 10-atom saturated or unsaturated alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or N-R41, wherein R41 is H, C1-6 alkyl, cycloalkyl or -C(O)-R42, wherein R42 is C1-6 alkyl, cycloalkyl or C6 or 10 aryl; R4 is H or from one to three substituents at any carbon atom of said chain D, said substituent independently selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxy, halo, amino, oxo, thio or C1-6 thioalkyl, and A is an amide of formula -C(O)-NH-R5, wherein R5 is selected from the group consisting of: C1-8 alkyl, C3-6 cycloalkyl, C6 or 10 aryl or C7-16 aralkyl; or A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof.
本发明包括在体外和细胞检测中对丙型肝炎病毒 NS3 蛋白酶具有活性的式 I 大环化合物。
其中 W 是 CH 或 N;R21 是 H、卤代、C1-6 烷基、环烷基、卤代烷基、C1-6 烷氧基、环烷氧基、羟基或 N(R23)2,其中每个 R23 独立地是 H、C1-6 烷基或环烷氧基;R22 是 H、卤素、C1-6 烷基、C3-6 环烷基、C1-6 卤代烷基、C1-6 硫代烷基、C1-6 烷氧基、C3-6 环烷氧基、C2-7 烷氧基烷基、C3-6 环烷基、C6 或 10 芳基或 Het,其中 Het 是含有一至四个选自氮、氧和硫的杂原子的五元、六元或七元饱和或不饱和杂环;所述环烷基、芳基或 Het 被 R24 取代,其中 R24 是 H、C1-6 烷基、C3-6 环烷基、C1-6 烷氧基、C3-6 环烷氧基、NO2、N(R25)2、NH-C(O)-R25 或 NH-C(O)-NH-R25,其中每个 R25 独立地是:H、C1-6 烷基或 C3-6 环烷基;或 R24 是 NH-C(O)-OR26,其中 R26 是 C1-6 烷基或 C3-6 环烷基;R3 是羟基、NH2 或式-NH-R31 的基团,其中 R31 是 C6 或 10 芳基、杂芳基、-C(O)-R32、-C(O)-OR32 或-C(O)-NHR32,其中 R32 是:C1-6烷基或C3-6环烷基; D是5至10原子的饱和或不饱和亚烷基链,可任选含有1至3个独立选自以下的杂原子: O、S或N-R41,其中R41是H、C1-6烷基、环烷基或-C(O)-R42,其中R42是C1-6烷基、环烷基或C6或10芳基; R4是H或在所述链D的任一碳原子上的1至3个取代基,所述取代基独立选自以下组成的组:C1-6烷基、C1-6卤代烷基、C1-6烷氧基、羟基、卤代、氨基、氧代、硫代或 C1-6 硫代烷基,以及 A 是式-C(O)-NH-R5 的酰胺,其中 R5 选自由下列组成的组C1-8 烷基、C3-6 环烷基、C6 或 10 芳基或 C7-16 芳烷基;或 A 是羧酸或其药学上可接受的盐或酯。